EP2 receptor agonists

1. A compound of formula (1)

wherein

A is O—CH 2 —, —CH═CH—or —CH 2 —CH 2 —,

X is hydrogen or C 1 -C 4 -alkyl,

R1 is unsubstituted phenyl, phenyl substituted by R2 or phenyl substituted by R2 and

R3, wherein

R2 is —(CH 2 ) n —OH, —(CH 2 ) q NH 2 , halogen, —CH 2 —NH(CO)R21 , —O—(CO)—N(R22)(R23)

or

wherein

n is an integer from 0 to 4,

q is an integer from 1 to 4,

R21 is C 1 -C 4 -alkyl,

R22 is hydrogen or C 1 -C 2 -alkyl,

R23 is hydrogen or C 1 -C 2 -alkyl,

R24 is NR25, CH 2 , O or S

wherein

R25 is hydrogen or C 1 -C 2 -alkyl,

R3 is —(CH 2 ) p —OH,

wherein

p is an integer from 0 to 2, and

R4 is hydrogen or halogen,

or a salt, a solvate, or a solvate of the salt, of formula (1).

2. The compound according to claim 1 ,

wherein

A is —O—CH 2 —, —CH═CH—or —CH 2 —CH 2 —,

X is hydrogen or C 1 -C 2 -alkyl,

R1 is unsubstituted phenyl, phenyl substituted by R2 or phenyl substituted by R2 and R3, wherein

R2 is —(CH 2 ) n —OH, —(CH 2 ) q NH 2 , halogen, —CH 2 —NH(CO)R21 , —O—(CO)—N(R22)(R23)

or

wherein

n is an integer from 0 to 2,

q is 1 or 2

R21 is C 1 -C 2 -alkyl,

R22 is hydrogen or C 1 -C 2 -alkyl,

R23 is hydrogen or C 1 -C 2 -alkyl,

R24 is NR25, CH 2 , O or S,

wherein

R25 is hydrogen,

R3 is —(CH 2 ) p —OH,

wherein

p is 0 or 1, and

R4 is hydrogen or halogen.

3. The compound according to claim 1 ,

wherein

A is —O—CH 2 —, —CH═CH—or —CH 2 —CH 2 —,

X is hydrogen or C 1 -C 2 -alkyl,

R1 is unsubstituted phenyl, phenyl substituted by R2 or phenyl substituted by R2 and R3, wherein

R2 is —(CH 2 ) n —OH, —(CH 2 ) q NH 2 , halogen, —CH 2 —NH(CO)R21 , —O—(CO)—N(R22)(R23) or

wherein

n is an integer from 0 to 2,

q is 1,

R21 is C 1 -C 2 -alkyl,

R22 is C 1 -C 2 -alkyl,

R23 is C 1 -C 2 -alkyl,

R24 is NR25, CH 2 , O or S

wherein

R25 is hydrogen,

R3 is —(CH 2 ) p —OH,

wherein

p is 0, and

R4 is hydrogen, fluorine, chlorine or bromine.

4. The compound according to claim 3 ,

wherein

A is —O—CH 2 —, —CH═CH—or —CH 2 —CH 2 —,

X is hydrogen or C 1 -C 2 -alkyl,

R1 is unsubstituted phenyl, phenyl substituted by R2 or phenyl substituted by R2 and R3, wherein

R2 is —(CH 2 ) n —OH, fluorine, —CH 2 —NH(CO)R21, —O—(CO)—N(R22)(R23) or

wherein

n is 0 or 1,

R21 is methyl,

R22 is methyl,

R23 is methyl,

R24 is NR25, CH 2 or O,

wherein

R25 is hydrogen,

R3 is —(CH 2 ) p —OH,

wherein

p is 0, and

R4 is hydrogen, fluorine or chlorine.

5. The compound according to claim 4 , which is selected from the group consisting of

(2E)-3-(3-{[(3-phenylnaphthalen-1-yl)carbonyl]amino}phenyl)prop-2-enoic acid,

(2E)-3-(4-fluoro-3-{[(3-phenylnaphthalen-1-yl)carbonyl]amino}phenyl)prop-2-enoic acid,

(2E)-3-(4-chloro-3-{[(3-phenylnaphthalen-1-yl)carbonyl]amino}phenyl) prop-2-enoic acid,

(3-{[(3-phenylnaphthalen-1-yl)carbonyl]amino}phenoxy)acetic acid,

(4-fluoro-3-{[(3-phenylnaphthalen-1-yl)carbonyl]amino}phenoxy)acetic acid,

(4-chloro-3-{[(3-phenylnaphthalen-1-yl)carbonyl]amino}phenoxy)acetic acid,

3-(3-{[(3-phenylnaphthalen-1-yl)carbonyl]amino}phenyl)propanoic acid,

3- (4-fluoro-3-{[(3-phenylnaphthalen-1-yl)carbonyl]amino }phenyl)propanoic acid,

(2E)-3-{3-[({3-[2-fluorophenyl]naphthalen-1-yl}carbonyl)amino]-4fluorophenyl}prop-2-enoic acid,

(2E)-3-{3-[({3-[3-fluorophenyl]naphthalen-1-yl}carbonyl)amino]-4fluorophenyl}prop-2-enoic acid,

(2E)-3-{3-[({3-[4-fluorophenyl]naphthalen-1-yl}carbonyl)amino]-4fluorophenyl}prop-2-enoic acid,

(2E)-3-{3-[({3-[3- (aminomethyl)phenyl]naphthalen-1-yl}carbonyl)amino]-4fluorophenyl}prop-2-enoic acid,

(2E)-3-{4-fluoro-3-[({3-[2-hydroxymethyl)phenyl]naphthalen-1-yl}carbonyl)amino]phenyl}prop-2-enoic acid,

(2E)-3-{4-fluoro-3-[({3-[3-(hydroxymethyl)phenyl]naphthalen-1-yl}carbonyl)amino]phenyl}prop-2-enoic acid,

(2E)-3-[4-fluoro-3-({[3-(3-fluoro-5-hydroxyphenyl)naphthalen-1yl]carbonyl}amino)phenyl]prop-2-enoic acid,

3-[4-fluoro-3-({[3-(2-fluorophenyl)naphthalen-1yl]carbonyl}amino)phenyl]propanoicacid,

3-[4-fluoro-3-({[3-(3-fluorophenyl)naphthalen-1-yl]carbonyl}amino)phenyl]propanoic acid,

(2E)-3-(3-{[(3-{3-[(acetylamino)methyl]phenyl}naphthalen-1-yl)carbonyl]amino }-4 fluorophenyl)prop-2-enoic acid,

(2E)-3-[3-({[3-(3-hydroxyphenyl)naphthalen-1-yl]carbonyl}amino)phenyl]prop-2-enoic acid,

(2E)-3-{3-[({3-[3-(piperazin- 1-yl)phenyl]naphthalen-1-yl}carbonyl)amino]phenyl}prop-2-enoic acid,

(2E)-3-[3-({[3-(morpholin-4-yl)naphthalen-1-yl]carbonyl}amino)phenyl]prop-2-enoic acid,

(2E)-3-[4-fluoro-3-({[3-(piperidin- 1-yl)naphthalen-1-yl]carbonyl}amino)phenyl]prop-2-enoic acid and

(2E)-3-(3-{[(3-{3-[(dimethylcarbamoyl)oxy]phenyl}naphthalen-1-yl)carbonyl]amino}phenyl)prop-2-enoic acid.

6. A pharmaceutical composition comprising

at least one of the compounds according to claim 1 , together with at least one pharmaceutically acceptable auxiliary.

7. A fixed combination, non-fixed combination or kit of parts comprising

at least one compound according to claim 1 ,

at least one therapeutic agent selected from the group consisting of corticosteroids, anticholinergics, β2-adrenoreceptor agonists, H1 receptor antagonists, leukotriene receptor antagonists, 5-lipoxygenase inhibitors, endothelin antagonists, type 4 phosphodiesterase inhibitors, type 5 phosphodiesterase inhibitors, theophylline, PPAR gamma agonists, Angiotensin 1 agonists, immunosuppressants, immune modulators, cytokine inhibitors, vitamin D analogues, HMG-CoA reductase-inhibitors, lung surfactants, antibiotics and any therapeutic with anti-inflammatory, anti-fibrotic or bronchodilatory action, and at least one pharmaceutically acceptable auxiliary.

8. A method of treating an acute or chronic airway disease selected from the group consisting of bronchial asthma, chronic asthmatic disorders with reduced lung function and airway hyperreactivity, bronchial acute exacerbations, chronic bronchitis, acute respiratory distress syndrome, chronic obstructive pulmonary disorder (COPD), pulmonary fibrosis, cystic fibrosis, and pulmonary artery hypertension, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1 .

9. The compound according to claim 1 , wherein the compound is

(2E)-3-(3-{[(3-phenylnaphthalen-1-yl)carbonyl]amino}phenyl)prop-2-enoic acid or a salt thereof.

10. The compound according to claim 1 , wherein the compound is (2E)-3-(4-fluoro-3-{[(3-phenylnaphthalen-1-yl)carbonyl]amino}phenyl)prop-2-enoic acid or a salt thereof.

11. The compound according to claim 1 , wherein the compound is (2E)-3-{3-[({3-[2-fluorophenyl]naphthalen-1-yl}carbonyl)amino]-4-fluorophenyl}prop-2-enoic acid or a salt thereof.

12. The compound according to claim 1 , wherein the compound is (2E)-3-{3-[({3-[3-fluorophenyl]naphthalen-1-yl}carbonyl)amino]-4-fluorophenyl}prop-2-enoic acid or a salt thereof.

13. A pharmaceutical composition comprising the compound according to claim 9 together with at least one pharmaceutically acceptable auxiliary.

14. A pharmaceutical composition comprising the compound according to claim 10 together with at least one pharmaceutically acceptable auxiliary.

15. A pharmaceutical composition comprising the compound according to claim 11 together with at least one pharmaceutically acceptable auxiliary.

16. A pharmaceutical composition comprising the compound according to claim 12 together with at least one pharmaceutically acceptable auxiliary.

17. A method of treating an acute or chronic airway disease selected from the group consisting of bronchial asthma, chronic asthmatic disorders with reduced lung function and airway hyperreactivity, bronchial acute exacerbations, chronic bronchitis, acute respiratory distress syndrome, chronic obstructive pulmonary disorder (COPD), pulmonary fibrosis, cystic fibrosis, and pulmonary artery hypertension comprising administering to a patient in need thereof a therapeutically effective amount of the compound according to claim 9 .

18. A method of treating an acute or chronic airway disease selected from the group consisting of bronchial asthma, chronic asthmatic disorders with reduced lung function and airway hyperreactivity, bronchial acute exacerbations, chronic bronchitis, acute respiratory distress syndrome, chronic obstructive pulmonary disorder (COPD), pulmonary fibrosis, cystic fibrosis, and pulmonary artery hypertension comprising administering to a patient in need thereof a therapeutically effective amount of the compound according to claim 10 .

19. A method of treating an acute or chronic airway disease selected from the group consisting of bronchial asthma, chronic asthmatic disorders with reduced lung function and airway hyperreactivity, bronchial acute exacerbations, chronic bronchitis, acute respiratory distress syndrome, chronic obstructive pulmonary disorder (COPD), pulmonary fibrosis, cystic fibrosis, and pulmonary artery hypertension comprising administering to a patient in need thereof a therapeutically effective amount of the compound according to claim 11 .

20. A method of treating an acute or chronic airway disease selected from the group consisting of bronchial asthma, chronic asthmatic disorders with reduced lung function and airway hyperreactivity, bronchial acute exacerbations, chronic bronchitis, acute respiratory distress syndrome, chronic obstructive pulmonary disorder (COPD), pulmonary fibrosis, cystic fibrosis, and pulmonary artery hypertension comprising administering to a patient in need thereof a therapeutically effective amount of the compound according to claim 12 .